Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: A case series

Therapeutic options are needed for metastatic melanoma refractory to therapies directed against programmed cell death-1. High-dose interleukin-2 has the potential to overcome programmed cell death-1 resistance.